Status: Recruiting
Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia
The primary objective of the study is to determine the recommended phase 2 dose (RP2D) of ziftomenib in combination with chemotherapy (FLA) in children with relapsed or refractory KMT2A-r, NUP98-r, or NPM1-m acute leukemia based on safety and pharmacokinetics (PK).
Participants needed: 20
Trial details
Phase: Phase 1Age: 0-21Biological sex: AllType: InterventionalSponsor: PedAL BCU, LLCUpdated: Oct 20, 2025Locations: 20
Eligibility criteria
Age: 0-21 years (and at least 5 kg body weight), with a minimum of 80% of partic... [+36]
Participants who in the opinion of the investigator may not be able to comply wi... [+18]